| Name | Title | Contact Details |
|---|
As the leading provider of targeted drug delivery (TDD) and infusion care, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected across our two divisions. ● A center of excellence in high-risk intrathecal compounding, AIS Healthcare Targeted Drug Delivery prepares and ships more than 140,000 patient-specific dispenses annually to all 50 states. We also offer comprehensive care services to support patients and empower providers, including in-home pump care and care coordination services. ● At Advanced Infusion Care, we provide high-quality intravenous (IV) and subcutaneous (SubQ) immunoglobulin therapies and in-home care to more than 1,500 patients across the country. Our nationally accredited home infusion team, including infusion nurse specialists and clinical pharmacists, partner closely with physicians to provide the best possible infusion care. AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
API Manufacturing Company
Taisho Pharmaceutical California is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.
Hanson Research is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.